[{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2025-02-25T12:26:33.859Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"e892208a-36f9-4d6f-a38c-e7cd64d31bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659136","created_at":"2021-01-18T17:57:27.537Z","updated_at":"2025-02-25T12:26:58.565Z","phase":"Phase 2","brief_title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","source_id_and_acronym":"NCT03659136","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2025-02-24"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"ea690cf4-a21c-4998-8096-bc622dfec937","acronym":"GeparPiPPa","url":"https://clinicaltrials.gov/study/NCT05306041","created_at":"2022-03-31T16:52:51.318Z","updated_at":"2025-02-25T14:16:47.877Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","source_id_and_acronym":"NCT05306041 - GeparPiPPa","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PGR positive","tags":["HER-2 • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 01/02/2023","start_date":" 01/02/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-17"},{"id":"565c074b-8e2d-4c64-bf84-a85e904612da","acronym":"MACS","url":"https://clinicaltrials.gov/study/NCT04469296","created_at":"2021-01-18T21:28:40.655Z","updated_at":"2025-02-25T15:34:42.684Z","phase":"","brief_title":"Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery","source_id_and_acronym":"NCT04469296 - MACS","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/18/2021","start_date":" 05/18/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-11"},{"id":"343860fb-1c41-454c-a2e5-97b25f553d79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02954874","created_at":"2021-01-18T14:30:57.547Z","updated_at":"2025-02-25T16:44:03.478Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","source_id_and_acronym":"NCT02954874","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1155","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-06"},{"id":"583d3d4e-954b-4daf-9f41-90e56eda49dd","acronym":"DYNASTY-Breast02","url":"https://clinicaltrials.gov/study/NCT06018337","created_at":"2023-08-30T14:09:02.590Z","updated_at":"2025-02-25T16:40:10.354Z","phase":"Phase 3","brief_title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","source_id_and_acronym":"NCT06018337 - DYNASTY-Breast02","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)"],"overall_status":"Recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-06"},{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2025-02-25T16:43:29.841Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-02-06"},{"id":"c4e11efc-9d5b-4b66-8405-a37c7fb6999f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865992","created_at":"2021-01-18T19:04:02.353Z","updated_at":"2025-02-25T16:44:35.724Z","phase":"","brief_title":"Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease","source_id_and_acronym":"NCT03865992","lead_sponsor":"City of Hope Medical Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2025-02-06"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"0ed50171-eed5-449a-810c-57f1bdbbcb80","acronym":"OFSET","url":"https://clinicaltrials.gov/study/NCT05879926","created_at":"2023-05-30T14:05:14.431Z","updated_at":"2025-02-25T16:55:01.814Z","phase":"Phase 3","brief_title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","source_id_and_acronym":"NCT05879926 - OFSET","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 3960","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-02-04"},{"id":"4de118f4-f565-48f1-9ed6-83996e6bbbe2","acronym":"DEBRA","url":"https://clinicaltrials.gov/study/NCT04852887","created_at":"2021-04-21T11:53:33.835Z","updated_at":"2025-02-25T16:53:39.381Z","phase":"Phase 3","brief_title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","source_id_and_acronym":"NCT04852887 - DEBRA","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1670","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2041","study_completion_date":" 07/01/2041","last_update_posted":"2025-02-04"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"85201425-83fc-431f-9c04-0410092876c4","acronym":"TBCRC 050","url":"https://clinicaltrials.gov/study/NCT03368729","created_at":"2021-01-18T16:37:35.798Z","updated_at":"2025-02-25T13:12:32.252Z","phase":"Phase 1/2","brief_title":"Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT03368729 - TBCRC 050","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive • EGFR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-04"},{"id":"c392c236-bf01-4f33-b758-84c02e4596c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939897","created_at":"2021-01-18T19:24:01.905Z","updated_at":"2025-02-25T16:52:29.645Z","phase":"Phase 1","brief_title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03939897","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2020","start_date":" 06/17/2020","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-02-04"},{"id":"07e761fd-ab9e-4f8b-987c-e31d82b143b4","acronym":"OSU-13282","url":"https://clinicaltrials.gov/study/NCT02186470","created_at":"2021-01-18T10:12:08.297Z","updated_at":"2025-02-25T16:58:41.014Z","phase":"","brief_title":"Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients with Hormone Responsive Stage 0-I Breast Cancer","source_id_and_acronym":"NCT02186470 - OSU-13282","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 04/29/2016","start_date":" 04/29/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-03"},{"id":"fbf3716a-0c89-444d-8fe3-c713df6342b5","acronym":"RaPhLRR","url":"https://clinicaltrials.gov/study/NCT05467891","created_at":"2022-07-21T12:57:26.496Z","updated_at":"2025-02-25T15:54:32.807Z","phase":"Phase 2","brief_title":"Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05467891 - RaPhLRR","lead_sponsor":"Oana Danciu","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-31"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"895cc6e3-6ceb-4627-b2e2-941b32623452","acronym":"ADAPTcycle","url":"https://clinicaltrials.gov/study/NCT04055493","created_at":"2021-01-18T19:52:55.710Z","updated_at":"2025-02-25T15:43:39.169Z","phase":"Phase 3","brief_title":"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC","source_id_and_acronym":"NCT04055493 - ADAPTcycle","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1684","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-01-14"},{"id":"b1021c14-5399-4865-b4e3-db5fb8024093","acronym":"LYNK-002","url":"https://clinicaltrials.gov/study/NCT03742895","created_at":"2021-01-18T18:19:59.379Z","updated_at":"2025-02-25T15:08:07.786Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","source_id_and_acronym":"NCT03742895 - LYNK-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" PGR positive • BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-12-09"},{"id":"c4941059-797c-48e5-8562-88baff159bbc","acronym":"TBCRC 048","url":"https://clinicaltrials.gov/study/NCT03344965","created_at":"2021-01-17T17:24:38.311Z","updated_at":"2025-02-25T14:58:31.297Z","phase":"Phase 2","brief_title":"Olaparib in Metastatic Breast Cancer","source_id_and_acronym":"NCT03344965 - TBCRC 048","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HR positive • PALB2 mutation • PGR positive • BRCA mutation","tags":["PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PALB2 mutation • PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-11"},{"id":"79775896-981f-4795-860c-5b8a8ca129f9","acronym":"ADEPT","url":"https://clinicaltrials.gov/study/NCT04569747","created_at":"2021-01-18T21:49:27.045Z","updated_at":"2025-02-25T12:27:45.281Z","phase":"Phase 2","brief_title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","source_id_and_acronym":"NCT04569747 - ADEPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-10-01"}]